Last updated: March 7, 2026
What Is the Drug Associated With NDC 60846-0810?
NDC 60846-0810 is a medication marketed under the name Forteo (teriparatide). It is an injectable drug used to treat osteoporosis by stimulating new bone growth. Forteo is approved for use in postmenopausal women at high risk of fracture, men with osteoporosis, and patients with glucocorticoid-induced osteoporosis.
Market Overview
1. Segment and Indications
- Primary market: Osteoporosis treatment for high-risk populations.
- Additional indications: Osteosarcoma risk management remains theoretical, as no cases have been directly linked.
- Administration: Subcutaneous injection, typically once daily.
2. Market Size and Growth Drivers
- Global osteoporosis drugs market: Valued at approximately USD 12 billion in 2022; expected to grow at a compound annual growth rate (CAGR) of 3-4% through 2028.
- U.S. market share: Accounted for around 40% of global sales in 2022.
- Patient population: Estimated at 10 million in the U.S. with osteoporosis, with approximately 1.6 million receiving treatment.
3. Competitive Landscape
- Key competitors: Romosozumab (Evenity), bisphosphonates like alendronate, denosumab (Prolia).
- Market positioning: Forteo differentiates through its anabolic mechanism, suitable for patients with high fracture risk or who do not respond to antiresorptive agents.
4. Regulatory Factors
- Pricing and reimbursement: Controlled via Medicare, private insurance, and Medicaid. Pricing varies based on negotiated contracts, typically ranging from USD 2,600 to USD 3,200 per month.
- Patent status: U.S. patent protections extend into the mid-2020s; biosimilar entry is anticipated around 2024-2026.
Price Projections
1. Current Pricing Landscape
| Description |
Approximate Price (USD) |
Notes |
| Monthly retail price |
$2,600 – $3,200 |
Varies by provider and insurance |
| Annual cost |
$31,200 – $38,400 |
Based on 12 months usage |
| Wholesale acquisition cost (WAC) |
~$2,350 |
Estimated through standard coverage |
2. Short-term Forecast (Next 2 Years)
- Stability expected: Due to patent protection and limited biosimilar competition, prices are projected to remain within the current range.
- Reimbursement adjustments: Slight reductions possible as payers negotiate discounts and rebates.
- Market share: Slight increase in prescribing as awareness rises among clinicians and new guidelines favor anabolic agents for high-risk patients.
3. Mid- to Long-term Outlook (2024 and beyond)
- Biosimilar entry: Potential for price reductions of 20-30% post-biosimilar approvals.
- Pricing decline: Newer therapies like romosozumab may exert downward pressure.
- Market penetration: Increasing adoption for early intervention could stabilize or slightly raise prices if demand surges.
4. Sensitivity Factors
- Policy changes: Reimbursement policies favoring biosimilars could accelerate price reductions.
- Patent litigation: Delays in biosimilar launches can sustain higher pricing longer.
- Clinical guidelines: Revised recommendations affecting treatment algorithms impact demand and pricing.
Strategic Implications
- The absence of biosimilar competition for Forteo until mid-2020s supports stable or slightly declining prices in the near term.
- Significant price drops are expected with biosimilar entry, which could impact revenue streams for originator manufacturers.
- Market success depends on clinicians' adoption of anabolic therapies versus antiresorptive agents, especially in high-risk segments.
Key Takeaways
- NDC 60846-0810 corresponds to Forteo (teriparatide), a high-priced anabolic osteoporosis therapy.
- The global osteoporosis market grows modestly, with Forteo holding a niche focus for high-risk populations.
- Prices are projected to remain stable for the next two years, with possible declines of 20-30% post-biosimilar entry around 2024-2026.
- Biosimilar competition, policy changes, and evolving clinical guidelines will influence price trajectories.
- Manufacturers should monitor biosimilar development and reimbursement trends for strategic planning.
FAQs
Q1: What factors influence the pricing of Forteo?
Pricing is primarily affected by patent status, insurance negotiations, and competition from biosimilars. Reimbursement policies and manufacturer discounts also play a role.
Q2: Could biosimilar entry significantly reduce Forteo prices?
Yes, biosimilar approvals typically lead to 20-30% price reductions, although the exact impact depends on market adoption and regulatory delays.
Q3: How does Forteo compare with other osteoporosis treatments in price?
Forteo is among the more expensive options, with annual costs around USD 31,200 to USD 38,400. Bisphosphonates are cheaper, often costing less than USD 1,000 annually.
Q4: What are the main market challenges for Forteo?
Patent expiration, biosimilar competition, and shifts towards alternative therapies like romosozumab constrain pricing power.
Q5: How might new clinical guidelines affect Forteo's market?
They may either increase demand if anabolic therapies are recommended earlier or restrict use if guidelines favor antiresorptive agents for certain populations.
Sources:
[1] IQVIA. (2022). Global Osteoporosis Market Report.
[2] U.S. Food and Drug Administration. (2022). Forteo (teriparatide) prescribing information.
[3] EvaluatePharma. (2023). Biotech and Pharmaceutical Market Data.
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies for Osteoporosis Drugs.
[5] United States Patent and Trademark Office. (2023). Patent status of Forteo.
